BioCentury | Feb 22, 2020
Translation in Brief

Storm's open-access algorithm for RNA epigenetics; plus Duke studies show checkpoint blockers promote anti-HIV bNAbs and reduce opioid efficacy

Algorithm from Storm and academic collaborators for high-throughput analysis of RNA epigenetics  Storm Therapeutics Ltd. and collaborators at the University of Pennsylvania and the University of Tübingen have created a computational algorithm, Nucleic Acid Search...
BC Extra | Oct 31, 2019
Preclinical News

Oct. 31 Preclinical Quick Takes: Beam licenses tech from Prime Medicine; plus BioVersys, Astellas-Kyoto University and more

Beam expands base editing platform with prime editing  Beam Therapeutics disclosed single base transitions and sickle cell disease as the first applications of its sublicense to prime editing technology from newco Prime Medicine. With the...
BC Innovations | Oct 25, 2019
Tools & Techniques

Gladstone, Xyphos target universal CARs to latent HIV

Xyphos teamed up with the Gladstone Institutes to direct the company’s universal CAR Ts to cells latently infected with HIV, addressing several of the challenges CAR Ts have faced in the indication. Major barriers to...
BC Innovations | Aug 29, 2019
Distillery Therapeutics

Cytomegalovirus vectors could form the backbone of an HIV vaccine

DISEASE CATEGORY: Infectious diseases INDICATION: HIV/AIDS An engineered cytomegalovirus vector-based vaccine protected against successive SIV infections in monkeys, suggesting it could be used to create an HIV vaccine. Monkeys vaccinated with an rhesus CMV (RhCMV)...
BC Innovations | Mar 13, 2019
Distillery Therapeutics

Cocktails of AAV vectors encoding anti-HIV bNAbs to treat the infection

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Non-human primate studies suggest cocktails of viral vectors encoding broadly neutralizing antibodies (bNAbs) against multiple HIV antigens could help treat HIV. The antibodies consist of variable regions of previously...
BC Innovations | Mar 4, 2019
Distillery Therapeutics

gp120-binding bNAbs for HIV

DISEASE CATEGORY: Infectious disease INDICATION: HIV/AIDS Cell culture studies suggest broadly neutralizing antibodies (bNAbs) that bind two adjacent HIV gp120 monomers in HIV env could help prevent and treat HIV-1 infection. The bNAbs were generated...
BC Innovations | Dec 19, 2018
Distillery Therapeutics

Infectious disease

INDICATION: HIV/AIDS Non-human primate studies suggest soluble HIV env trimer given in combination with a saponin-based adjuvant could help prevent HIV infection. In macaques challenged with HIV, immunization with soluble HIV env trimer plus the...
BC Innovations | Oct 25, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Coronavirus; influenza virus; HIV/AIDS; Ebola Cell culture and rat studies identified lipopeptide-based inhibitors of MERS-CoV S protein, Ebola virus glycoprotein and HIV env that could help treat Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola...
BC Innovations | Aug 29, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Antibody scaffolds Sialylation of immune complexes could enhance the response to HIV vaccines. Patients who spontaneously controlled HIV without therapy and patients who had evolved neutralizing activity against a panel of 11 HIV-1 viruses...
BC Innovations | Aug 29, 2018
Distillery Techniques

Drug platforms; imaging

TECHNOLOGY: Structural analyses; other An electron microscopy-based method for identifying epitopes that elicit potent neutralizing antibodies could be used to guide the development of vaccines for infectious diseases. The method involves six steps: digesting animal-...
Items per page:
1 - 10 of 58